Clene shares are trading higher after the company announced long-term survival improvement from CNM-Au8 treatment in the HEALEY ALS Platform Trial compared to PRO-ACT historical controls.
Portfolio Pulse from Benzinga Newsdesk
Clene Inc. announced that its CNM-Au8 treatment in the HEALEY ALS Platform Trial showed long-term survival improvement compared to PRO-ACT historical controls. This news has led to an increase in Clene's share prices.
September 26, 2023 | 2:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Clene's stock is trading higher after the company announced positive results from its CNM-Au8 treatment in the HEALEY ALS Platform Trial.
The announcement of positive results from Clene's CNM-Au8 treatment in the HEALEY ALS Platform Trial has led to an increase in the company's share prices. This indicates a positive market reaction to the news, which could potentially continue in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100